Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi - LARVOL DELTA

How the multiple burdens of daily oral antiretroviral therapy shape the acceptability of long-acting injectable cabotegravir and rilpivirine among people living with HIV in Uganda and South Africa: a sub-study of the IMPALA trial. (PubMed, AIDS Care) - "Finally, prior experiences with routine HIV care services were contrasted with trial-based care that emphasised privacy, efficiency, respectful communication, and reimbursement of transportation costs. LAI-ART was preferred to daily oral ART as it reduced treatment burden, improved privacy and supported adherence."

Journal • Fatigue • Human Immunodeficiency Virus • Infectious Disease

Long-Term Outcomes of Cabotegravir-Rilpivirine Long-Acting Injectable Initiated in People with HIV with Recent Viremia: A National VHA Cohort Study (IDWeek 2026) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

Switching to Long-Acting Cabotegravir and Rilpivirine Without Historical Genotyping Availability: Effectiveness and Durability from the RELATIVITY Cohort (IDWeek 2026) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

Mental Health among Patients Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in an Urban Midwestern HIV Clinic: A Retrospective Cohort Study (IDWeek 2026) - No abstract available

Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Virologic Outcomes Following Transition to Long-Acting Injectable Cabotegravir/Rilpivirine: Comparison of Prior Two-Drug vs Three-Drug Oral Regimens (IDWeek 2026) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

Weight and Metabolic Outcomes in People Living with HIV Following Switch to Long-Acting Cabotegravir/Rilpivirine: A Retrospective Cohort Study (IDWeek 2026) - No abstract available

Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Persistence and Virologic Outcomes at 12 Months After Switch to Long-Acting Cabotegravir-Rilpivirine in Veterans With HIV: A Nationwide Matched Cohort Study (IDWeek 2026) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

Predictors of Successful Switch to Long-Acting Cabotegravir/Rilpivirine in a National Veterans Health Administration Cohort (IDWeek 2026) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

High Suppression and Rare Virologic Failure with Long-Acting Cabotegravir + Rilpivirine: Real World Evidence Over Five Years from the OPERA Cohort (IDWeek 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

Narrative Review of Two-Drug Regimens in Modern HIV Care: Driving Innovation, Flexibility, and Quality of Life. (PubMed, Infect Dis Ther) - "Dolutegravir/lamivudine, dolutegravir/rilpivirine and long-acting cabotegravir/rilpivirine are the regimens studied the most, supported by randomised trials and real-world evidence. Long-acting injectable strategies may be particularly valuable for individuals who face challenges with daily oral adherence or treatment-related stigma. This narrative review summarizes current evidence on the role of oral and injectable 2DRs in key domains including innovation, flexibility, tolerability, adherence and quality of life, while discussing current limitations and future perspectives."

HEOR • Journal • Review • Human Immunodeficiency Virus • Infectious Disease

Long-acting cabotegravir and rilpivirine in people with HIV and cancer: Virological eligibility and DDI considerations. (PubMed, Br J Clin Pharmacol) - "Most ART-experienced PWH with cancer were eligible for LAI CAB/RPV, while many had conditions potentially limiting oral ART. Candidate selection should integrate clinical need, virological eligibility, pharmacological assessment and patient-related factors through a multidisciplinary approach."

Journal • Human Immunodeficiency Virus • Infectious Disease • Oncology

Persistent Injection-Site Nodules After the Administration of Long-Acting Cabotegravir/Rilpivirine. (PubMed, Intern Med) - No abstract available

Journal • Human Immunodeficiency Virus • Infectious Disease

Well-being in people with HIV after one year of long-acting cabotegravir and rilpivirine. (PubMed, AIDS Care) - "Compared to the questionnaires completed at baseline, the median negative Well-Being score was lower (p = 0.05). Our study supported that CAB/RPV can improve some aspects of well-being in PWH, mostly related to emotional distress; however, the general well-being score remained stable over one year of follow-up."

Journal • Human Immunodeficiency Virus • Infectious Disease

Direct Initiation of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV and Suboptimal Virologic Suppression: A Randomized Trial. (PubMed, Clin Infect Dis) - "Among people with HIV and viremia associated with adherence challenges, immediate initiation of LA CAB+RPV resulted in higher rates of viral suppression than continued oral ART, supporting its use beyond populations with stable suppression."

Journal • Human Immunodeficiency Virus • Infectious Disease

Impact of implementation process on long-acting cabotegravir/rilpivirine prescription at 9 HIV clinics, 2021-2024. (PubMed, J Acquir Immune Defic Syndr) - "Barriers related to insurance coverage and drug procurement impacted the number of PWH prescribed LA-CAB/RPV as did processes to plan for, and adapt to, these barriers. Scale-up efforts should consider team coordination and EHR-facilitated tracking to support the growing number of PWH on LA-CAB/RPV."

Journal • Human Immunodeficiency Virus • Infectious Disease

Financial Impact of a Long-Acting Injectable Cabotegravir/Rilpivirine Program: A Real-World Experience. (PubMed, Clin Infect Dis) - "Although LAI CAB/RPV requires double the staff time and generates less time-adjusted PI than oral ART, buy-and-bill LAI programs can remain financially viable. Payer mix and insurance stability are essential to ensuring sustainability and equitable access."

Journal • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

Hepatitis C Reactivation After Sustained Virologic Response in HIV-Positive Patient on Long-Acting Injectable Cabotegravir and Rilpivirine (ACG 2026) - "The patient was discontinued from the cabotegravir / rilpivirine and was started on oral bictegravir/emtricitabine/tenofovir alafenamide for treatment of his HIV. Additionally, the patient was prescribed 12 weeks of oral sofosbuvir/velpatasvir for treatment of his hepatitis C. The patient completed treatment and improved clinically...It is unsafe for patients to have long acting injectables without close follow up. Figure: Right Upper Quadrant Ultrasound showing "starry sky" appearance of the liver."

Clinical • Autoimmune Hepatitis • Genetic Disorders • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Movement Disorders

CREATE: Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy (clinicaltrials.gov) - P=N/A | N=40 | Not yet recruiting | Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Initiation date: Jul 2026 ➔ Oct 2026

Trial initiation date • Human Immunodeficiency Virus • Infectious Disease

Long-Acting Cabotegravir/Rilpivirine in Viremic Individuals: Interpreting Success Beyond Virologic Suppression. (PubMed, Clin Infect Dis) - No abstract available

Journal

Long-acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real-world case series. (PubMed, Br J Clin Pharmacol) - "This real-world case series suggest that chronic anticoagulant therapy alone should not automatically preclude the use of LA-CAB + RPV. With careful patient selection and appropriate injection techniques, LA-CAB + RPV may represent a safe and effective treatment option for selected people with HIV receiving anticoagulation."

Journal • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

Patient-Reported Outcomes with Long-Acting Cabotegravir and Rilpivirine in People Living with HIV. (PubMed, Patient Prefer Adherence) - "The subanalysis of the oral ART group revealed no significant differences in MOS-HIV and IEXPAC questionnaires, compared to LA therapy. PLWH receiving CAB+RPV LA as an alternative to daily oral ART, demonstrate high satisfaction, maintained quality of life and positive relationships with healthcare professionals."

Journal • Human Immunodeficiency Virus • Infectious Disease

Post-marketing safety signals, therapeutic failure, and product-use issues reported with injectable Cabenuva: A FAERS disproportionality analysis. (PubMed, J Public Health Res) - "This study provides a broad post-marketing signal-screening profile of Cabenuva, highlighting both known safety concerns and real-world implementation issues such as missed doses, administration problems, product issues, and therapeutic failure. The findings support careful clinical monitoring, adherence to administration guidance, staff training, and further validation of sparse unexpected signals."

Journal • P4 data • CNS Disorders • Depression • Human Immunodeficiency Virus • Infectious Disease • Pain • Psychiatry

Sustained Virologic Suppression After Discontinuation of Long-acting Cabotegravir/Rilpivirine: A Two-case Series Highlighting Unexpected Heterogeneity in Pharmacokinetics and Viral Control. (PubMed, Open Forum Infect Dis) - "The literature reports another similar case of sustained virologic control 18 months after LA CAB/RPV discontinuation despite inadequate adherence on oral antiretroviral treatment. Altogether, these cases underscore the need for further research to better understand the pharmacological and viro-immunological mechanisms underlying this phenomenon."

Clinical • Heterogeneity • Journal • PK/PD data • Anal Carcinoma • Human Immunodeficiency Virus • Infectious Disease • Oncology • Solid Tumor

Inter- and intraindividual variability of long-acting injectable cabotegravir/rilpivirine trough concentrations after 1 year of continuous use. (PubMed, J Antimicrob Chemother) - "After one year of continuous use, inter- and intraindividual variability persists for cabotegravir and rilpivirine, indicating that clinical decisions should not be based on only one trough concentration."

Journal • Human Immunodeficiency Virus • Infectious Disease

Differential pharmacokinetic decay of long-acting cabotegravir and rilpivirine after missed injections: a case series. (PubMed, J Antimicrob Chemother) - No abstract available

Journal • PK/PD data